Last $77.07 USD
Change Today +0.10 / 0.13%
Volume 197.6K
GEVA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Open
$77.36
Previous Close
$76.97
Day High
$79.33
Day Low
$76.23
52 Week High
02/28/14 - $119.42
52 Week Low
11/6/13 - $44.54
Market Cap
2.6B
Average Volume 10 Days
213.0K
EPS TTM
$-4.70
Shares Outstanding
33.2M
EX-Date
12/30/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNAGEVA BIOPHARMA CORP (GEVA)

Related News

No related news articles were found.

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL), which is under Phase III clinical trials for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy for lysosomal storage diseases, known as mucopolysaccharidosis type IIIB, as well as protein therapeutic programs for rare life-threatening diseases. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

172 Employees
Last Reported Date: 03/4/14
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $601.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $360.5K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $380.1K
Executive Vice President of Medical and Regul...
Total Annual Compensation: $379.6K
Senior Vice President of Global Commercial Op...
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2013.

synageva biopharma corp (GEVA) Key Developments

Synageva Biopharma Corp. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Business Updates

Synageva BioPharma Corp. reported consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $2,343,000 compared to $3,413,000 a year ago. Loss from operations was $50,313,000 compared to $22,190,000 a year ago. Loss before provision for income taxes was $50,224,000 compared to $22,190,000 a year ago. Net loss was $50,240,000 or $1.52 per basic and diluted share compared to $22,107,000 or $0.81 per basic and diluted share a year ago. For the six months, the company reported total revenue of $3,929,000 compared to $8,531,000 a year ago. Loss from operations was $86,789,000 compared to $36,763,000 a year ago. Loss before provision for income taxes was $86,630,000 compared to $36,763,000 a year ago. Net loss was $86,664,000 or $2.69 per basic and diluted share compared to $36,763,000 or $1.35 per basic and diluted share a year ago. The company plans to initiate clinical trial sites later this year and dose the first patient with intravenous administration of SBC-103 in a Phase 1/2 study in patients with mucopolysaccharidosis IIIB (MPS IIIB) by late 2014 or early 2015. This is based upon longer-term preclinical toxicology data expected during the second half of 2014 that could support a longer Phase 1/2 clinical trial than originally planned. Synageva continues to plan to advance two additional programs into clinical trials by the end of 2016. The company's pipeline programs include proteins targeting rare diseases at various stages of preclinical development.

Synageva BioPharma Corp. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:00 AM

Synageva BioPharma Corp. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:00 AM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: Sanj K. Patel, Chief Executive Officer, President, Secretary and Director.

Synageva BioPharma Corp. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-13-2014 08:00 AM

Synageva BioPharma Corp. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-13-2014 08:00 AM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Sanj K. Patel, Chief Executive Officer, President, Secretary and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $77.07 USD +0.10

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies
 

Industry Analysis

GEVA

Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 290.1x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 230.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit www.synageva.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.